

In The Claims:

✓
Please amend claims 10 and 11 as follows:

Subt
C2
B5
10. (Amended) A method for preventing and/or combatting diseases or disease states which are caused by increased leucocytic elastase or plasmin activity or can be is treated by the inhibition of normal leucocytic elastase or plasmin activity, said method comprising administering an effective amount of boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or [a plant preparation] containing boswellic acid to prevent and/or combat said diseases to a mammalian organism in need of such (prevention and/or combatting.)

11. (Amended) The method as claimed in claim 10, wherein said disease is pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis or rheumatoid arthritis, which are caused by increased leucocytic elastase activity, or wherein said disease state is growth of tumors and neoplasm or tumor metastases which are caused by increased plasmin activity.

REMARKS

Entry of the foregoing, reexamination and further and favorable reconsideration of the subject application in light of the following remarks pursuant to and consistent with 37 C.F.R. § 1.112, are respectfully requested.

By the foregoing amendment, claims 10 and 11 have been amended in order to clarify applicant's claimed invention. Support for these amendments can be found, at the very least, at page 6, lines 20-31, and at page 7, line 29, to page 8, line 2. Boswellic acid